Grant: Project Grant - PA: Neurosciences, Mental Health and Addiction
Université Laval
$100,000.00
Mechanisms of action of sex-specific endocrine treatments in animal models of Parkinson's disease
FY 2022-23
Summary
Parkinson's disease (PD) is well documented to be higher in men than in women and this sex difference could be due to effects of sex hormones. Drugs for PD only improve motor symptoms: no drug is yet available to limit disease progression. It is thus important to identify drugs that would interfere with disease progression. During previous CIHR-funded studies, we identified that estradiol and progesterone are neuroprotective in a neurotoxin (MPTP) mouse model of PD. We also found that the drug dutasteride (modulating steroid metabolism), already used in men, to be a potent neuroprotective and anti-inflammatory agent in this model. Neuroprotection with dutasteride was only observed in intact male mice, whereas in intact females their endogenous sex hormones were already protective against mild MPTP lesions. The mechanism of action of dutasteride and steroids involved are still unknown. We hypothesize that endogenous ratios of various androgens, estrogens and progestogens are modulated by dutasteride. Sex-specific treatments will be studied in various mouse models of PD (neurotoxin MPTP, genetic synucleionopathy and disease propagation) to investigate both sporadic and genetic forms of the disease.
In male mice, we will determine whether dutasteride beneficial effect is mainly mediated by increased endogenous brain estradiol using various pharmacological approaches. Intact and ovariectomized female mice will be compared, considering that women with sporadic PD are mainly menopausal with reduced ovarian activity. Specific estrogen and progesterone treatments for the brain will be evaluated to avoid risks of gonadal cancer. Neuroprotection and inflammation will be assessed in brain, gut and gonads, using bioanalytical and histopathological methods.
This project will validate novel mechanisms of action for hormone-modulating drugs already approved for human treatment to accelerate their use in PD. This project has high translational potential for sex-specific treatment.
Department
Program
Project Grant - PA: Neurosciences, Mental Health and Addiction
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
473166
Name
Soulet Denis
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Mechanisms of action of sex-specific endocrine treatments in animal models of Parkinson's disease
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Neurosciences, Mental Health and Addiction
Keyworddelim
Endocrinology; Mptp; Neuroinflammation; Neuroprotection; Parkinson; Preform-Fibrils; Sex-Differences; Synucleinopathy
Abstract
Parkinson's disease (PD) is well documented to be higher in men than in women and this sex difference could be due to effects of sex hormones. Drugs for PD only improve motor symptoms: no drug is yet available to limit disease progression. It is thus important to identify drugs that would interfere with disease progression. During previous CIHR-funded studies, we identified that estradiol and progesterone are neuroprotective in a neurotoxin (MPTP) mouse model of PD. We also found that the drug dutasteride (modulating steroid metabolism), already used in men, to be a potent neuroprotective and anti-inflammatory agent in this model. Neuroprotection with dutasteride was only observed in intact male mice, whereas in intact females their endogenous sex hormones were already protective against mild MPTP lesions. The mechanism of action of dutasteride and steroids involved are still unknown. We hypothesize that endogenous ratios of various androgens, estrogens and progestogens are modulated by dutasteride. Sex-specific treatments will be studied in various mouse models of PD (neurotoxin MPTP, genetic synucleionopathy and disease propagation) to investigate both sporadic and genetic forms of the disease.
In male mice, we will determine whether dutasteride beneficial effect is mainly mediated by increased endogenous brain estradiol using various pharmacological approaches. Intact and ovariectomized female mice will be compared, considering that women with sporadic PD are mainly menopausal with reduced ovarian activity. Specific estrogen and progesterone treatments for the brain will be evaluated to avoid risks of gonadal cancer. Neuroprotection and inflammation will be assessed in brain, gut and gonads, using bioanalytical and histopathological methods.
This project will validate novel mechanisms of action for hormone-modulating drugs already approved for human treatment to accelerate their use in PD. This project has high translational potential for sex-specific treatment.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Soulet, Denis; Di Paolo-Chenevert, Thérèse
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~